Akero Therapeutics Inc
(STU:0K4)
€
29.02
-1.63 (-5.32%)
Market Cap: 2.04 Bil
Enterprise Value: 1.40 Bil
PE Ratio: 0
PB Ratio: 3.02
GF Score: 34/100 Akero Therapeutics Inc Phase 2B HARMONY Trial Data Presentation Transcript
Sep 13, 2022 / 12:00PM GMT
Release Date Price:
€28
(+143.48%)
William White
Akero Therapeutics - EVP, CFO, Treasurer & Head of Corporate Development
Presentation
Sep 13, 2022 / 12:00PM GMT
=====================
Corporate Participants
=====================
* William White
Akero Therapeutics - EVP, CFO, Treasurer & Head of Corporate Development
* Andrew Cheng
Akero Therapeutics - President, CEO & Director
* Kitty Yale
Akero Therapeutics - EVP & Chief Development Officer
* Tim Rolph
Akero Therapeutics - Co-Founder & Chief Scientific Officer
=====================
Conference Call Participants
=====================
* Eric Joseph
JPMorgan Chase & Co - Analyst
* Ed Nash
Canaccord Genuity Corp - Analyst
* Ed Arce
H.C. Wainwright & Co, LLC - Analyst
=====================
-
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot